GoodRx (NASDAQ:GDRX) Trading Down 3% After Insider Selling

Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) dropped 3% on Thursday after an insider sold shares in the company. The company traded as low as $4.78 and last traded at $4.90. Approximately 638,080 shares were traded during trading, a decline of 55% from the average daily volume of 1,414,575 shares. The stock had previously closed at $5.05.

Specifically, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the business's stock in a transaction on Thursday, July 3rd. The stock was sold at an average price of $4.80, for a total value of $51,249.60. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on GDRX. The Goldman Sachs Group decreased their price objective on GoodRx from $6.00 to $5.00 and set a "neutral" rating on the stock in a research note on Friday, May 9th. Wells Fargo & Company decreased their price objective on GoodRx from $8.00 to $7.00 and set an "overweight" rating on the stock in a research note on Tuesday, April 29th. UBS Group decreased their price objective on GoodRx from $6.00 to $5.25 and set a "neutral" rating on the stock in a research note on Tuesday, May 13th. Finally, Truist Financial decreased their price objective on GoodRx from $6.50 to $5.50 and set a "hold" rating on the stock in a research note on Thursday, April 10th. Five analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $6.55.

GoodRx Price Performance

The company has a market capitalization of $1.70 billion, a PE ratio of 59.49, a PEG ratio of 2.09 and a beta of 1.24. The firm has a fifty day moving average of $4.35 and a two-hundred day moving average of $4.52. The company has a current ratio of 5.23, a quick ratio of 5.23 and a debt-to-equity ratio of 0.74.

GoodRx (NASDAQ:GDRX - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.09 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.05. GoodRx had a return on equity of 7.85% and a net margin of 3.57%. The business had revenue of $202.97 million during the quarter, compared to analysts' expectations of $202.25 million. During the same quarter last year, the business posted $0.08 EPS. The business's revenue was up 2.6% on a year-over-year basis. Research analysts anticipate that GoodRx Holdings, Inc. will post 0.13 EPS for the current fiscal year.

Institutional Investors Weigh In On GoodRx

Several institutional investors and hedge funds have recently bought and sold shares of the business. National Bank of Canada FI raised its position in shares of GoodRx by 34.9% in the 4th quarter. National Bank of Canada FI now owns 8,308 shares of the company's stock worth $39,000 after acquiring an additional 2,151 shares in the last quarter. Citizens Financial Group Inc. RI bought a new position in shares of GoodRx in the 1st quarter worth approximately $44,000. Jump Financial LLC bought a new position in shares of GoodRx in the 1st quarter worth approximately $49,000. RPO LLC bought a new position in shares of GoodRx in the 4th quarter worth approximately $52,000. Finally, Steward Partners Investment Advisory LLC bought a new position in shares of GoodRx in the 4th quarter worth approximately $56,000. Hedge funds and other institutional investors own 63.77% of the company's stock.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.